Outcomes in primary Raynaud phenomenon: A meta-analysis of the frequency, rates, and predictors of transition to secondary disease

Archives of Internal Medicine

Volumn 158, Issue 6, 1998, Pages 595-600

  Spencer Green, George ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY;

ADULT; ARTICLE; CONNECTIVE TISSUE DISEASE; DISEASE PREDISPOSITION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SEROLOGY; SKIN CAPILLARY; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME;

ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RAYNAUD DISEASE; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC;

EID: 0032559806     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.6.595     Document Type: Article

References (51)

1. Campbell PM, LeRoy EC. Raynaud phenomenon. Semin Arthritis Rheum. 1986; 16:92-103.
2. Coffman JD. The enigma of primary Raynaud's disease. Circulation. 1989;80: 1089-1090.
3. Spencer-Green G. Raynaud phenomenon. Bull Rheum Dis. 1984;33:1-8.
4. Cleophas TJ, Niemeyer MG. Raynaud's syndrome, an enigma after 130 years. Angiology. 1993;44:196-209.
5. Klippel JH. Raynaud's phenomenon: the French tricolor. Arch Intern Med. 1991; 151:2389-2393.
6. Inaba R, Maeda M, Fujita S, et al. Prevalence of Raynaud's phenomenon and specific clinical signs related to progressive systemic sclerosis in the general population of Japan, Int J Dermatol. 1993;32:652-655.
7. de Trafford JC, Lafferty K, Potter CE, Roberts VC, Cotton LT. An epidemiological survey of Raynaud's phenomenon. Eur J Vasc Surg. 1988;2:167-170.
8. Maricq HR, Weinrich MC, Keil JE, LeRoy EC. Prevalence of Raynaud phenomenon in the general population: a preliminary study by questionnaire. J Chronic Dis. 1986;39:423-427.
9. Olsen N, Nielsen SL. Prevalence of Raynaud phenomena in young females. Scand J Clin Lab Invest. 1978;38:761-764.
10. Porter JM, Bardana EJ Jr, Baur GM, Wesche DH, Andrasch RH, Rosch J. The clinical significance of Raynaud's syndrome. Surgery. 1976;80:756-764.
11. Kallenberg CG, Pastoor GW, Wouda AA, The TH. Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies. Ann Rheum Dis. 1982;41:382-387.
12. Allen EV, Brown GE. Raynaud's disease: a critical review of minimal requisites for diagnosis. Am J Med Sci. 1932;183:187-192.
13. Sheiner NM, Small P. Isolated Raynaud's phenomenon - a benign disorder. Ann Allergy. 1987;58:114-117.
14. Maricq HR, Weinberger AB, LeRoy EC. Early detection of scleroderma-spectrum disorders by in vivo capillary microscopy: a prospective study of patients with Raynaud's phenomenon. J Rheumatol. 1982;9:289-291.
15. Masi AT, Rodnan GP, Medsger TA Jr, et al. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23:581-590.
16. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-1277.
17. Arnett FC, Edworthy SM, Bloch DA. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31:315-324.
18. Vitali C, Bombardieri S, Moutsopoulos HM, et al. Preliminary criteria for the classification of Sjögren's syndrome. Arthritis Rheum. 1993;36:340-347.
19. Miller FW. Classification and prognosis of inflammatory muscle disease. Rheum Dis Clin North Am. 1994;20:811-826.
20. Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease: an apparently distinct rheumatic disease syndrome associated with a specific antibody to extractable nuclear antigen (ENA). Am J Med. 1972;52:148-154.
21. Landry GJ, Edwards JM, McLafferty RB, Taylor LM Jr, Porter JM. Long-term outcome of Raynaud's syndrome in a prospectively analyzed patient cohort. J Vasc Surg. 1996;23:76-85.
22. Weiner ES, Hildebrandt S, Senecal JL, et al. Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease: a prospective study. Arthritis Rheum. 1991;34:68-77.
23. Gentric A, Blaschek MA, Le Noach JF, et al. Serological arguments for classifying Raynaud's phenomenon as idiopathic. J Rheumatol. 1990;17:1177-1181.
24. Wollersheim H, Thien T, Hoet MH, Van Venrooy WJ. The diagnostic value of several immunological tests for anti-nuclear antibody in predicting the development of connective tissue disease in patients presenting with Raynaud's phenomenon. Eur J Clin Invest. 1989;19:535-541.
25. Zufferey P, Depairon M, Cnamot AM, Monti M. Prognostic significance of nailfold capillary microscopy in patients with Raynaud's phenomenon and scleroderma-pattern abnormalities: a six-year follow-up study. Clin Rheumatol. 1992;11:536-541.
26. Kallenberg CG, Wouda AA, Hoet MH, van Venrooij WJ. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis. 1988;47:634-641.
27. FitzGerald O, Hess EV, O'Connor GT, Spencer-Green G. Prospective study of the evolution of Raynaud's phenomenon. Am J Med. 1988;84:718-726.
28. Priollet P, Vayssairat M, Housset E. How to classify Raynaud's phenomenon: longterm follow-up study of 73 cases. Am J Med. 1987;83:494-498.
29. Gerbracht DD, Steen VD, Ziegler GL, Medsger TA Jr, Rodnan GP. Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease. Arthritis Rheum. 1985;28:87-92.
30. Harper FE, Maricq HR, Turner BE, Lidman RW, LeRoy EC. A prospective study of Raynaud phenomenon and early connective tissue disease: a five-year report. Am J Med. 1982;72:883-888.
31. Hirschl M, Kundi M. Initial prevalence and incidence of secondary Raynaud's phenomenon inpatients with Raynaud's symptomatology. J Rheumatol. 1996;23: 302-309.
32. Mulrow CD, Linn WD, Gaul MK, Pugh JA. Assessing quality of a diagnostic test evaluation. J Gen Intern Med. 1989;4:288-295.
33. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-748.
34. Fleiss JL. Statistical Methods for Rates and Proportions. New York, NY: John Wiley & Sons Inc; 1981.
35. StataCorp. State Statistical Software: Release 4.0. College Station, Tex: StataCorp; 1995.
36. Dictionary of the Rheumatic Diseases. Vol 1: Signs and Symptoms. New York, NY: Contact Associates International Ltd; 1982.
37. Ohtsuka T, Ishikawa H. Statistical definition of nail fold capillary pattern in patients with systemic sclerosis. Dermatology. 1994;188:286-289.
38. Michoud E, Poensin D, Carpentier PH. Digitized nailfold capillaroscopy. Vasa. 1994;23:35-42.
39. Statham BN, Rowell NR. Quantification of the nail fold capillary abnormalities in systemic sclerosis and Raynaud's syndrome. Acta Derm Venereol. 1986;66:139-143.
40. Lee P, Leung FY, Alderdice C, Armstrong SK. Nailfold capillary microscopy in the connective tissue diseases: a semiquantitative assessment. J Rheumatol. 1983; 10:930-938.
41. Maricq HR, Maize JC. Nailfold capillary abnormalities. Clin Rheum Dis. 1982;8: 455-478.
42. Bollinger A, Jager K. New ways of studying the cutaneous microcirculation in clinical medicine [in German]. Arzneimittelforschung. 1981;31:2015-2019.
43. Minkin W, Rabhan NB. Office nail fold capillary microscopy using ophthalmoscope. J Am Acad Dermatol. 1982;7:190-193.
44. Maricq HR, LeRoy EC, D'Angelo WA, et al. Diagnostic potential of in vivo capil-lary microscopy in scleroderma and related disorders. Arthritis Rheum. 1980; 23:183-189.
45. Maricq HR, Spencer-Green G, LeRoy EC. Skin capillary abnormalities as indicators of organ involvement in scleroderma (systemic sclerosis), Raynaud's syndrome and dermatomyositis. Am J Med. 1976;61:862-870.
46. Spencer-Green G, Alter D, Welch G. Test performance in systemic sclerosis: anti-centromere and anti-Scl-70 antibodies. Am J Med. 1997;103:242-248.
47. Alarcon GS, Williams GV, Singer JZ, et al. Early undifferentiated connective tissue disease, I: early clinical manifestation in a large cohort of patients with undifferentiated connective tissue diseases compared with cohorts of well established connective tissue disease. J Rheumatol. 1991;18:1332-1339.
48. Clegg DO, Williams HJ, Singer JZ, et al. Early undifferentiated connective tissue disease, II: the frequency of circulating antinuclear antibodies in patients with early rheumatic diseases. J Rheumatol. 1991;18:1340-1343.
49. Lawrence RC, Hochberg MC, Kelsey JL, et al. Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. J Rheumatol. 1989;16:427-441.
50. Lally EV, Jimenez SA, Kaplan SR. Progressive systemic sclerosis: mode of presentation, rapidly progressive disease course, and mortality based on an analysis of 91 patients. Semin Arthritis Rheum. 1988;18:1-13.
51. LeRoy EC, Medsger TA Jr. Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol. 1992;10:485-488.